The use of selected clinically validated HDAC inhibitors, which have already shown promising therapeutic efficacy in AML patients [98], in combination with GLI antagonists may therefore be an attractive therapeutic approach in GLI-dependent cancer entities. This evidence concerns the gene GLI1 and cancer.